Results 11 to 20 of about 75,353,973 (171)

AI-assisted analysis of early fluid dynamics following aflibercept 8 mg in treatment-naïve neovascular AMD. [PDF]

Eye (Lond)
Abstract Purpose To evaluate early morphological changes following intravitreal aflibercept 8 mg in treatment-naïve neovascular age-related macular degeneration (nAMD) using artificial intelligence (AI)-assisted optical coherence tomography (OCT) segmentation.
Veritti D, Sarao V, Martin AA, Bonini F, Lanzetta P.   +4 more
europepmc   +4 more sources

Aflibercept 8 mg: From Ocular Clearance to Pharmacodynamic Duration [PDF]

CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 10, October 2026.
Daniele Veritti, Valentina Sarao, Paolo Lanzetta   +2 more
doaj   +3 more sources

Reply to “Aflibercept 8 mg: From Ocular Clearance to Pharmacodynamic Duration” [PDF]

CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 11, November 2026.
Sébastien Bihorel, Joannellyn Chiu, Jason Chittenden, Thomas Eissing, Kenneth C. Turner, Joachim Höchel, Zhongqing Will He, John D. Davis, Lutz O. Harnisch   +8 more
doaj   +3 more sources

High-Dose 8 mg Aflibercept for Neovascular Age-Related Macular Degeneration: Who Is Being Treated with This New Agent?

Life
Purpose: To describe the indication spectrum for high-dose 8 mg aflibercept for neovascular age-related macular degeneration (nAMD) in a real-world cohort in a tertiary referral center.
Caspar Liesenhoff, Carolin Meyrl, Daniel Krause, Franziska Eckardt, Anna Lorger, Viktoria Deiters, Johannes Schiefelbein, Julian Elias Klaas, Benedikt Schworm, Siegfried G. Priglinger, Jakob Siedlecki   +10 more
doaj   +2 more sources

Deep learning-assisted analysis of biomarker changes after increase of dosing from aflibercept 2 mg to 8 mg in therapy-resistant neovascular age-related macular degeneration

BMJ Open Ophthalmology
Purpose Age-related macular degeneration (AMD) remains the leading cause of blindness in developed countries. There are many different intravitreal anti-vascular endothelial growth factor (VEGF) drugs available for the treatment of neovascular AMD (nAMD).
Siegfried Priglinger, Jakob Siedlecki, Benedikt Schworm, Franziska Eckardt, Michael Hafner, Ben Asani, Caspar Liesenhoff, Alexander Kufner, Johannes Benedikt Schiefelbein   +8 more
doaj   +2 more sources

One-Month Real-World Comparison of Aflibercept 8 mg Versus 2 mg in Treatment-Naïve and Previously Treated Eyes with Neovascular Age-Related Macular Degeneration

Biologics
Background/Objectives: The relative efficacy of 8 mg aflibercept compared to 2 mg in treating neovascular age-related macular degeneration (nAMD) has not been fully established. This study aims to compare the visual and anatomical outcomes of aflibercept
Takahiro Mizukami, Satoru Ueno, Soichiro Mishima, Yoshikazu Shimomura   +3 more
doaj   +2 more sources

Intraocular inflammation after intravitreal injection of aflibercept 8 mg for treatment-refractory neovascular age-related macular degeneration: a case report

BMC Ophthalmology
Background To report a case of intraocular inflammation (IOI) after intravitreal injection of aflibercept 8 mg for treatment-refractory neovascular age-related macular degeneration.
Nozomu Hashiya, Ichiro Maruko, Yuri Miyaguchi, Ruka Maruko, Taiji Hasegawa, Tomohiro Iida   +5 more
doaj   +2 more sources

Faricimab 6 mg versus aflibercept 8 mg in diabetic macular oedema: an in silico study of anchored efficacy and common-protocol treatment burden [PDF]

Frontiers in Pharmacology
BackgroundNo prospective randomised head-to-head trial has compared faricimab 6 mg with aflibercept 8 mg for diabetic macular oedema (DMO). Their pivotal programmes used materially different dosing architectures, precluding interpretation of observed ...
Georgios D. Panos, Georgios D. Panos
doaj   +2 more sources

Short-term efficacy of aflibercept 8 mg in refractory neovascular age-related macular degeneration: a retrospective case series from Taiwan [PDF]

BMC Ophthalmology
Purpose Aflibercept 8 mg is a newly developed option for neovascular age-related macular degeneration (nAMD) class. This study explores the short-term effectiveness of aflibercept 8 mg in patients with refractory nAMD.
Sheng-Chu Chi, De-Kuang Hwang, Shih-Jen Chen, Chang-Chi Weng, Yi Ming Huang, Yu-Bai Chou, Tai-Chi Lin   +6 more
doaj   +2 more sources

Evaluation of aflibercept and ziv-aflibercept binding affinity to vascular endothelial growth factor, stability and sterility after compounding

International Journal of Retina and Vitreous, 2018
Purpose To investigate the binding affinity, stability, and sterility of aflibercept and ziv-aflibercept to vascular endothelial growth factor (Holash et al. in Proc Natl Acad Sci USA 99(17):11393–11398, 2002.
Julia de Lima Farah, Ronaldo Sano, Ieda Maria Longo Maugéri, Daniela Teixeira, Mayari Eika Ishimura, Gabriela Martins, Lycia M. J. Mimica, Cely Barreto da Silva, Carsten H. Meyer, João Rafael de Oliveira Dias, Gabriel Costa de Andrade, Michel Eid Farah   +11 more
doaj   +2 more sources